Monkeypox is a zoonosis caused by monkeypox virus. The virus was first discovered in 1958 in monkeys kept for research, and hence the disease was named ‘monkeypox’.
Since first reported in humans in 1970 in the Democratic Republic of Congo (then known as Zaire), most of the reported monkeypox outbreaks have occurred in Central and West Africa.
The symptoms are similar to those of smallpox, but in milder forms. The first few days after infection with monkeypox are characterised by fever, intense headache, myalgia and lymphadenopathy. Severe swollen lymph nodes before the appearance of rash could be a distinctive feature of monkeypox. Lesions in mouth and body appear about 1 to 3 days after onset of fever. The lesions progress from maculopapules to vesicles, pustules and followed by crusts within a period of 10 days to two weeks and the lesions typically progress simultaneously at all parts of the body.
Monkeypox is usually a self-limited disease with symptoms lasting from 14 to 21 days. The case fatality in previous monkeypox outbreaks has been between 1% and 10%.
Mode of transmission
Infection could occur when a person comes into contact with the virus from infected animals, infected humans or contaminated materials. Humans could get infected from various wild animals, such as some species of primates, rodents and squirrels, etc., through bite or scratch, or direct contact with their body fluids. Human-to-human transmission is also possible through respiratory droplets during prolonged face-to-face contact or direct contact with body fluids.
The incubation period is usually from 6 to 13 days, with a range from 5 to 21 days.
The Government has procured a third generation vaccine called "JYNNEOS" by making reference to the earlier recommendations of the Scientific Committee on Vaccine Preventable Diseases and the Scientific Committee on Emerging and Zoonotic Diseases (JSC) under the Centre for Health Protection. The vaccine has arrived in Hong Kong in September 2022 to be used in the Monkeypox Vaccination Programme. "JYNNEOS" has been licensed by the U.S. Food and Drug Administration (FDA) for the protection of monkeypox in 2019. A new antiviral drug has been approved for the treatment of monkeypox in Europe recently.
To reduce the risk of infection, members of the public travelling to places affected by monkeypox virus should:
|Bahasa Indonesia Version